The US Food and Drug Administration approved the first-ever vaccine to treat cancer on 29 April. After a three-year battle with the regulatory agency and three phase 3 trials, the treatment—called Provenge, by Seattle-based Dendreon—extended median survival time in men with advanced prostate cancer by more than four months. (Click here to continue reading)
Image by Zaldylmg via Flickr Creative Commons
Recent comments
Real-time tissue analysis could guide brain tumor surgery
Bundled RNA balls silence brain cancer gene expression
Ebola outbreak in West Africa lends urgency to recently-funded research